Pradaxa has also been approved to reduce the risk of recurrent venous thromboembolism patients who have previously been treated.
In clinical trials, Pradaxa demonstrated a 92 percent reduction of risk of recurrent blood clots compared to a placebo, according to the news release.
More Articles on FDA Approvals:
FDA Clears Intuitive Surgical’s Latest da Vinci Robot Upgrade
FDA Approves Alprolix for Hemophilia B Treatment
FDA Approves Otezla for Psoriatic Arthritis Treatment
